Type | Charitable organisation |
---|---|
Focus | Alzheimer's disease research Health policy |
Key people | Hilary Evans (Chief Executive) |
Website | www |
Formerly called | Alzheimer's Research Trust |
Alzheimer's Research UK (ARUK) is a dementia research charity in the United Kingdom, founded in 1992 as the Alzheimer's Research Trust.
ARUK funds scientific studies to find ways to treat, cure or prevent all forms of dementia, including Alzheimer's disease, vascular dementia, dementia with Lewy bodies and frontotemporal dementia.
As of 2019, Alzheimer's Research UK has funded 139 research projects across the UK and internationally, and has committed more than £117 million to dementia research. [1]
Alzheimer's Research UK is a member of the Association of Medical Research Charities.
In 1998, the trust awarded its first major grant of £500,000 to a team led by distinguished scientist Dr Michel Goedert in Cambridge. At that time the charity funded over 100 grants all over the UK at a cost of more than £11 million. [2]
In March 2008, author Terry Pratchett, who had the disease, donated one million US dollars to the trust. [3]
In February 2010, the Alzheimer's Research Trust released the Dementia 2010 report, revealing new evidence of the prevalence, economic cost and research funding for dementia and other major conditions. [4] [5]
In 2016, Alzheimer's Research UK became a founding funder of the UK Dementia Research Institute, a £290 million joint investment with the Medical Research Council and Alzheimer's Society. [6]
In 2017, former Prime Minister David Cameron was appointed president of Alzheimer's Research UK. [7]
Alzheimer's Research UK and Alzheimer's Society were the joint Charity of the Year for the 2019 Virgin Money London Marathon. The Dementia Revolution campaign raised £4 million, supporting research at the UK Dementia Research Institute. [8]
The charity reported a total income of £38.5m for the 12-month period ending March 2019, £36.7m of which was income from donations. [9]
In 2023, estimates made by Alzheimer's Research UK suggested that clinical trials for lecanemab and donanemab would only find 575,000 people living in the UK eligible for treatment. The challenge was, these people needed a diagnosis but the National Health Service couldn't deliver at that scale. This was because of the risks of side effects, few PET scanners to diagnose Alzheimer's and limited skilled professionals to perform lumbar punctures. [10]
Sir Terence David John Pratchett was an English author, humorist, and satirist, best known for the Discworld series of 41 comic fantasy novels published between 1983–2015, and for the apocalyptic comedy novel Good Omens (1990), which he co-wrote with Neil Gaiman.
Dementia is a syndrome associated with many neurodegenerative diseases, characterized by a general decline in cognitive abilities that affects a person's ability to perform everyday activities. This typically involves problems with memory, thinking, behavior, and motor control. Aside from memory impairment and a disruption in thought patterns, the most common symptoms of dementia include emotional problems, difficulties with language, and decreased motivation. The symptoms may be described as occurring in a continuum over several stages. Dementia ultimately has a significant effect on the individual, their caregivers, and their social relationships in general. A diagnosis of dementia requires the observation of a change from a person's usual mental functioning and a greater cognitive decline than might be caused by the normal aging process.
Lewy body dementia (LBD) is an umbrella term for two similar and common subtypes of dementia: dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD). Both are characterized by changes in thinking, movement, behavior, and mood. The two conditions have similar features and may have similar causes, and are believed to belong on a spectrum of Lewy body disease that includes Parkinson's disease. As of 2014, they were more often misdiagnosed than any other common dementia.
Cancer Research UK (CRUK) is the world's largest independent cancer research organisation. It is registered as a charity in the United Kingdom and Isle of Man, and was formed on 4 February 2002 by the merger of The Cancer Research Campaign and the Imperial Cancer Research Fund. Cancer Research UK conducts research using both its own staff and grant-funded researchers. It also provides information about cancer and runs campaigns aimed at raising awareness and influencing public policy.
The Wellcome Trust is a charitable foundation focused on health research based in London, United Kingdom. It was established in 1936 with legacies from the pharmaceutical magnate Henry Wellcome to fund research to improve human and animal health. The aim of the Trust is to "support science to solve the urgent health challenges facing everyone." It had a financial endowment of £29.1 billion in 2020, making it the fourth wealthiest charitable foundation in the world. In 2012, the Wellcome Trust was described by the Financial Times as the United Kingdom's largest provider of non-governmental funding for scientific research, and one of the largest providers in the world. According to their annual report, the Wellcome Trust spent GBP £1.1 billion on charitable activities across their 2019/2020 financial year. According to the OECD, the Wellcome Trust's financing for 2019 development increased by 22% to US$327 million.
The British Heart Foundation (BHF) is a cardiovascular research charity in the United Kingdom. It funds medical research related to heart and circulatory diseases and their risk factors, and runs influencing work aimed at shaping public policy and raising awareness.
Alzheimer's Society is a United Kingdom care and research charity for people with dementia and their carers. It operates in England, Wales and Northern Ireland, while its sister charities Alzheimer Scotland and Alzheimer Society of Ireland cover Scotland and the Republic of Ireland respectively.
Parkinson's UK is a Parkinson's research and support charity in the United Kingdom. In April 2010, the Parkinson's Disease Society changed its name to become Parkinson's UK. Its aims are to improve the quality of life for people affected by Parkinson's and find a cure for the condition.
The Alzheimer Society of Ontario (ASO) is a care and research charity committed to helping people living with Alzheimer's disease and other dementias by:
Alzheimer’s Disease International (ADI) is a not-for-profit, international federation of Alzheimer and dementia associations from around the world. The organization is in official relations with the World Health Organization (WHO). ADI advocates for people living with Alzheimer’s disease and all other types of dementia.
Posterior cortical atrophy (PCA), also called Benson's syndrome, is a rare form of dementia which is considered a visual variant or an atypical variant of Alzheimer's disease (AD). The disease causes atrophy of the posterior part of the cerebral cortex, resulting in the progressive disruption of complex visual processing. PCA was first described by D. Frank Benson in 1988.
Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens, and is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events. As the disease advances, symptoms can include problems with language, disorientation, mood swings, loss of motivation, self-neglect, and behavioral issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the average life expectancy following diagnosis is three to twelve years.
The Alzheimer Society of Canada (ASC) is a Canadian health charity for people living with Alzheimer's disease and other dementias. Active in communities right across Canada, the Society partners with Alzheimer Societies in every Canadian province to offer information, support and education programs for people with dementia, their families and caregivers. The Alzheimer Society of Canada acts as the national voice for the thousands of Canadians living with dementia and advocates on their behalf for positive change. The Society also funds young and established Canadian researchers working to find the causes and a cure through the Alzheimer Society Research Program.
The UCL Queen Square Institute of Neurology is an institute within the Faculty of Brain Sciences of University College London (UCL) and is located in London, United Kingdom. Together with the National Hospital for Neurology and Neurosurgery, an adjacent facility with which it cooperates closely, the institute forms a major centre for teaching, training and research in neurology and allied clinical and basic neurosciences.
LifeArc is a British life science medical research charity. It was established in 2000 as MRC Technology to translate the work of UK Medical Research Council (MRC) research scientists.
BrightFocus Foundation is a nonprofit organization based in Clarksburg, Maryland. BrightFocus funds research in an effort to discover cures for Alzheimer's disease, macular degeneration and glaucoma, and provides information and free English and Spanish resources to increase awareness about these diseases. Through its research programs — Alzheimer’s Disease Research, National Glaucoma Research, and Macular Degeneration Research — the Foundation has awarded nearly $290 million in research funding. BrightFocus provides free public education and free printed brochures and publications on brain and eye diseases in English and Spanish, including Alzheimer's disease, macular degeneration, and glaucoma. BrightFocus has active research grants in 17 countries and at 154 institutions. BrightFocus Foundation offers free monthly low-vision audio podcast programs with medical experts on Glaucoma and Macular Degeneration and a free expert Alzheimer's video series called "Zoom in On Alzheimer's and Dementia" with medical doctors.
The Alzheimer's Foundation of America (AFA) is an American nonprofit organization based in New York City whose mission is to provide support, services and education to individuals, families and caregivers affected by Alzheimer's disease and related dementias nationwide, and fund research for better treatment and a cure. AFA unites more than 2,000 member organizations from coast-to-coast that are dedicated to meeting the educational, social, emotional and practical needs of individuals with Alzheimer's disease and related illnesses, and their caregivers and families. Member organizations include grassroots Alzheimer's agencies, senior centers, adult daycare center, home healthcare agencies, long-term care residences, research facilities, and other dementia-related groups. AFA holds Charity Navigator's highest rating of 4 stars.
The Foundation for the National Institutes of Health (FNIH) is a not-for-profit, 501(c)(3) charitable organization established by the US Congress in 1990. Located in North Bethesda, MD, the FNIH raises private-sector funds, and creates and manages alliances with public and private institutions in support of the mission of the National Institutes of Health (NIH).
Dementia and Alzheimer's disease in Australia is a major health issue. Alzheimer's disease is the most common type of dementia in Australia. Dementia is an ever-increasing challenge as the population ages and life expectancy increases. As a consequence, there is an expected increase in the number of people with dementia, posing countless challenges to carers and the health and aged care systems. In 2018, an estimated 376,000 people had dementia; this number is expected to increase to 550,000 by 2030 and triple to 900,000 by 2050. The dementia death rate is increasing, resulting in the shift from fourth to second leading cause of death from 2006 to 2015. It is expected to become the leading cause of death over the next number of years. In 2011, it was the fourth leading cause of disease burden and third leading cause of disability burden. This is expected to remain the same until at least 2020.
California Proposition 14 is a citizen-initiated ballot measure that appeared on the ballot in the 2020 California elections, for November 3, 2020. It authorizes state bonds to be issued worth $5.5 billion, which will fund the California Institute for Regenerative Medicine (CIRM), which serves as the state's center for stem cell research, and enable it to continue its operations. This measure passed with 51% of the vote.